August 2013: Nimotuzumab in MOGA Australia
Medical Oncology Group of Australia
Similar Posts
Webinar – The Role of Nimotuzumab in the Treatment of Head and Neck and Nasopharyngeal Cancer
ByInnokeys
This webinar was conducted on May 28th, 2022 discussing the role of Nimotuzumab in the treatment of locally advanced squamous cell…
June 2017: Poster Presentation at ANZCHOG 2017
ByInnokeys
Adelaide, South Australia (June 20, 2017) – Innokeys Pte Ltd attended ANZCHOG 2017 – a conference which is organized annually by the…
Update on Laryngeal Cancer
ByInnokeys
Speakers: 1. dr. Denny Satria Utama, Sp.T.H.T.L(K)., M.Si Med., FICS from Charitas Hospital Indonesia 2. Dr. dr. Fauziah Fardizza, Sp.T.H.T.K.L(K), FICS from…
Daiichi Sankyo Enrolls First Patient in Nimotuzumab Phase 3 Clinical Trials
ByInnokeys
Tokyo, Japan (April 25, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been enrolled in…
ASCO 2013 : Nimotuzumab Abstracts
ByInnokeys
Professor Dirk Strumberg from Germany (center, in blue suit), the principal investigator of phase IIB/IIIA nimotuzumab clinical trial on pancreatic cancer, in…
Webinar – Treatment Optimization in Locally Advanced & Metastatic Pancreatic Cancer-Tailored Patient Approach with Targeted Therapy
ByInnokeys
Prof. Dr. Dirk Strumberg, Oncologist in Marien Hospital Herne, Germany